Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EPIRUBICIN Cause Diffuse large b-cell lymphoma recurrent? 60 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 60 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with EPIRUBICIN (Ellence). This represents 0.4% of all adverse event reports for EPIRUBICIN.

60
Reports of Diffuse large b-cell lymphoma recurrent with EPIRUBICIN
0.4%
of all EPIRUBICIN reports
36
Deaths
5
Hospitalizations

How Dangerous Is Diffuse large b-cell lymphoma recurrent From EPIRUBICIN?

Of the 60 reports, 36 (60.0%) resulted in death, 5 (8.3%) required hospitalization, and 5 (8.3%) were considered life-threatening.

Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EPIRUBICIN. However, 60 reports have been filed with the FAERS database.

What Other Side Effects Does EPIRUBICIN Cause?

Nausea (1,265) Vomiting (978) Myelosuppression (934) Neutropenia (926) White blood cell count decreased (873) Febrile neutropenia (809) Diarrhoea (749) Asthenia (732) Pyrexia (729) Fatigue (685)

What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?

RITUXIMAB (1,359) CYCLOPHOSPHAMIDE (1,007) VINCRISTINE (957) DOXORUBICIN (953) PREDNISONE (738) CYTARABINE (406) DEXAMETHASONE (402) ETOPOSIDE (375) CISPLATIN (306) GEMCITABINE (280)

Which EPIRUBICIN Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?

EPIRUBICIN vs EPLERENONE EPIRUBICIN vs EPLONTERSEN EPIRUBICIN vs EPOETIN ALFA-EPBX EPIRUBICIN vs EPOGEN EPIRUBICIN vs EPOPROSTENOL

Related Pages

EPIRUBICIN Full Profile All Diffuse large b-cell lymphoma recurrent Reports All Drugs Causing Diffuse large b-cell lymphoma recurrent EPIRUBICIN Demographics